Cancers, Vol. 9, Pages 121: The PI3K δ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL

This report tests PI3Kδ inhibitors in a more diverse group of ALL than has been previously reported and is the first published report of idelalisib inhibiting homing of ALL cells to bone marrow. Our data support further pre-clinical evaluation of idelalisib for the therapy of B ALL.

Source: Cancers - September 10, 2017 Category: Cancer & Oncology Authors: Etai Adam Hye Na Kim Eun Ji Gang Caitlin Schnair Solomon Lee Solah Lee Sajad Khazal Osanna Kosoyan Marina Konopleva Chintan Parekh Deepa Bhojwani Alan S. Wayne Hisham Abdel-Azim Nora Heisterkamp Yong-Mi Kim Tags: Article Source Type: research